Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4441-4450 Newer>

The Motley Fool December 20, 2007 Brian Orelli	What Was That Clinical Trial For? EPIX Pharmaceuticals initiates a phase 2A study of its Alzheimer's disease drug, PRX-03140, to get safety and tolerability information. Instead, it got good efficacy data.
Chemistry World December 19, 2007 Hepeng Jia	Boom and Bust for Antimalarial Industry At first there was a global shortage, but now a surplus of artemisinin threatens to put some drug manufacturers out of business.
The Motley Fool December 19, 2007 Brian Lawler	Novartis' Diabetes Battle Can Begin Novartis gets set to market a novel diabetes treatment, with EU approval that is not all it had hoped for.
The Motley Fool December 19, 2007 Brian Orelli	New Beta Blocker on the Crowded Street Forest and Mylan receive FDA approval for Bystolic. Investors, take note.
The Motley Fool December 18, 2007 Brian Orelli	Bristol-Myers' Sleeker Image Just 12 days after announcing its restructuring plan, Bristol-Myers Squibb has found a buyer for its medical-imaging division and plans to close the deal by the end of next month.
The Motley Fool December 18, 2007 Brian Lawler	Cervarix Won't Save Glaxo Yet The FDA has another delay for this HPV vaccine. The agency has completed its review, but still has questions.
The Motley Fool December 18, 2007 Brian Lawler	PDL Liquidation Sale Begins PDL BioPharma's sale of a chemotherapy drug indicates it could recoup what it paid for ESP Pharma. Investors, take note.
The Motley Fool December 18, 2007 Brian Lawler	The Final Nail in Neurochem's Coffin The European Medicines Agency announced its refusal to approve Neurochem's lead drug, KIACTA.
HBS Working Knowledge December 17, 2007 Martha Lagace	The Rise of Medical Tourism Medical tourism is a new term but not a new idea. Patients have long traveled in search of better care. Today, constraints and long waiting lists at home, as well as the ease of global travel, make medical tourism more appealing.
The Motley Fool December 17, 2007 Brian Orelli	A Range of Changes for Stent Makers The FDA is about to make it harder for drug-eluting stents to win its approval.
<Older 4441-4450 Newer> Return to current articles.